In addition, anti-PD-1, anti-PD-L1, anti-CTLA-4, chemotherapy, anti-PD-1 plus chemotherapy, anti-PD-1 plus targeted therapy, and chemotherapy plus targeted therapy all showed markedly higher risk of AKI than targeted therapy. This evidence concerns the gene CTLA4 and acute kidney injury.